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                    ABSTRACT 
      In recent years the spread of extended-spectrum  f3-lactamase 
(ESBL)-producing microorganisms is increasing in hospital settings around the 
world. The prevalence of and risk factors associated with ESBL-producing 
microorganisms have not been well studied among asymptomatic individuals in 
communities. Therefore, the aim of this study was to determine this in healthy 
individuals in Thailand and Japan. 
     The study sampleswere collected in Thailand and Japan: 445 samples 
from Thailand during 2008-2009 and 417 samples in 2010; and 443 samples 
from Japan during 2009-2010. One stool sample and a questionnaire were 
obtained from each participant. Stool samples were screened for ESBLs using 
MacConkey agar supplemented with cefotaxime. Results were confirmed using 
cefotaxime and ceftazidime with and without clavulanic acid in accordance with 
the Clinical and Laboratory Standards Institute recommendations. The  b/acTx-ivi 
genes were identified and genotyped using PCR with bacterial DNA samples. 
Multivariate logistic regression analysis was performed to investigate risk factors 
associated with the faecal carriage of CTX-M producers. 
     In our first part of the study we identified high prevalence of CTX-M-type 
ESBL-producing Enterobacteriaceae in the three provinces of Thailand: 29.3% 
in Nan, 29.9% in Nakhon Si Thammarat and 50.6% in Kanchanaburi. 
Genotyping of  blac-rx_m revealed that most CTX-M producers harboured genes 
belonging to the CTX-M-9 group, followed by the CTX-M-1 group.  Escherichia 
 coil was the predominant member of the Enterobacteriaceae producing 
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CTX-M-type ESBLs. No statistically significant association was observed 
between the presence of ESBL-producing bacteria and gender, age, education, 
food habits or antibiotic usage. However, the provinces that had the highest 
prevalence of ESBL-producing Enterobacteriaceae also had the highest 
prevalence of use and purchase of antibiotics without a prescription. 
     After 2 years since the initial study we conducted another study in 
Kanchanaburi province with a more detailed questionnaire and increased the 
number of participants. The prevalence of CTX-M-type ESBL-producing 
Enterobacteriaceae was increased to 65.7%. Similar to previous findings, the 
CTX-M-9 group (60.6%) was dominant, followed by the CTX-M-1 group (38.7%). 
Most of the bacteria were E.  colt (85.4%) and  Klebsiella pneumoniae (4.7%). In a 
multivariate logistic regression model, better education status, history of 
hospitalization and the use of antibiotics within the last 3 months were 
independently associated with faecal carriage. 
     In contrast, faecal carriage of CTX-M producers among asymptomatic 
Japanese people was very low (6.0%). CTX-M-9 group was dominant, followed 
by CTX-M-2 group. E.  colt was predominantly identified among CTX-M 
producers. Statistical analysis did not reveal any significant association between 
ESBL production and antibiotic usage or hospitalization experience. However, 
the prevalence of CTX-M-producers in nursing homes of Japan was much higher 
(19.6%). In multivariate logistic regression analysis, inability to turn over in bed, 
diabetes, and invasive procedures within the last 2 years were the only variables 
independently associated with faecal carriage of CTX-M-type ESBL producers 
among nursing home residents. 
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      In summary, faecal carriage of CTX-M-type ESBL-producing 
Enterobacteriaceae among asymptomatic individuals in rural Thailand is 
alarmingly high, and previous antibiotic use and a history of hospitalization may 
contribute to its dissemination. In comparison to Thailand, faecal carriage of 
ESBL producers in healthy Japanese people is low but has an increasing trend. 
This may also be one of the causes of the increased spread of ESBL-producing 
bacteria in hospitals or vise versa, with nursing homes acting as a possible 
reservoir for community spread of CTX-M producers.
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               CHAPTER 1. INTRODUCTION 
1.1. Beta-lactam antibiotics and resistance to  13-lactams 
 13-Lactams comprise a very large family of different groups of bactericidal 
compounds all containing 13-lactam ring and inhibit bacterial cell wall synthesis 
by binding to penicillin-binding proteins (PBPs).1 Class and subclass designation 
and generic names of  13-lactam antibiotics are shown in Table 1.1. 
     Resistance to  13-lactams may involve one or more of the three possible 
mechanisms:1 
1. Resistance by alteration in target site, 
2. Resistance by alteration in access to the target site, 
3. Resistance by production of  13-lactamases. 
In gram-negative bacteria,  8-lactamases are the major defense against multiple 
classes of  13-lactam  antibiotics.2 
1.2. Beta-lactamases and ESBLs 
 13-Lactamases are enzymes that catalyze the hydrolysis of the  8-lactam 
ring and inactivate these antibiotics before they reach PBPs located at the 
cytoplasmic membrane.3 Genes encoding for these enzymes are found on the 
chromosome and on plasmids.1 Hundreds of different  13-lactamase enzymes 
have been described and by late 2009, the number of unique protein sequences 
exceeded  890.4 All  I3-lactamases have same function but with differing amino 
acid-sequences their spectra of  8-lactam substrates change. A group of 
 13-lactamases specifically target the newer  13-lactam antibiotics, including 
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Table 1.1.  13-Lactams: class and subclass designation and generic name 
(adapted from Clinical and Laboratory Standards  Institutes)
Antimicrobial
Class
Antimicrobial
Subclass
Agents Included; Generic Names
Penicillins Penicillina Penicillin
Aminopenicillina Amoxicillin, Ampicillin
Ureidopenicillina  Azlocillin,  Mezlocillin, Piperacillin
Carboxypenicillina Carbenicillin, Ticarcillin
 Penicillinase-stable
 penicillinsb
Cloxacillin, Dicloxacillin, Methicillin, Nafcillin, Oxacillin
Amidinopenicillin Mecillinam
 13-Lactam/13-lactamase
inhibitor combinations
Amoxicillin-clavulanic acid, Ampicillin-sulbactam,
Piperacillin-tazobactam, Ticarcillin-clavulanic acid
Cephems (parenteral) Cephalosporin IC Cefazolin, Cephalothin, Cephapirin, Cephradine
Cephalosporin  Ilc Cefamandole, Cefonicid, Cefuroxime (parenteral)
Cephalosporin  III` Cefoperazone, Cefotaxime, Ceftazidime,
Ceftizoxime, Ceftriaxone
Cephalosporin Cefepime
Cephalosporins with
anti-MRSA activity
Ceftaroline, Ceftobiprole
Cephamycin  Cefmetazole, Cefotetan, Cefoxitin
Oxacephem Moxalactam
Cephems (oral) Cephalosporin Cefaclor, Cefadroxil, Cefdinir, Cefditoren, Cefetamet,
Cefixime, Cefpodoxime, Cefprozil, Ceftibuten,
Cefuroxime (oral), Cephalexin, Cephradine
Carbacephem Loracarbef
Monobactams  Aztreonam
Penems Carbapenem Doripenem, Ertapenem,  Imipenem, Meropenem,
Razupenem
Penem Faropenem, Sulopenem
  Abbreviations: ESBL, extended-spectrum  p-lactamase; MRSA, methicillin-resistant S. aureus. 
 aPenicillinase labile; hydrolyzed by staphylococcal penicillinase
. 
 bNot hydrolyzed by staphylococcal penicillinase. 
'  cCephalos
porin I, II, Ill, and IV are sometimes referred to as 1st-, 2nd-, 3rd-, and 4th-generation 
  cephalosporins, respectively. Cephalosporin  III and IV are also referred to as "extended-spectrum 
  cephalosporins". This does not imply activity against ESBL-producing ram-negativebacteria. 
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extended-spectrum cephalosporins. First report of plasmid-encoded 
13-lactamases capable of hydrolyzing the extended-spectrum cephalosporins 
was published in 1983 and was soon followed by discoveries of other 
 8-lactamases with similar abilities, and hence these new  13-lactamases were 
named as Extended-Spectrum  §-Lactamases or ESBLs.6 
1.3. Definition of ESBLs 
     There is no consensus of the precise definition of ESBLs. A commonly 
used working definition is that the ESBLs are  13-lactamases capable of conferring 
bacterial resistance to the penicillins, first-, second-, and third-generation 
cephalosporins, and aztreonam (but not to cephamycins or carbapenems) by 
hydrolysis of these antibiotics and which are inhibited by  f3-lactamase inhibitors 
such as clavulanic  acid." 13-Lactamase inhibitors are molecules that contain a 
 13-lactam ring and act as "suicide inhibitors" binding to  13-lactamases and 
preventing them from destroying  13-lactams.1 
1.4. Classification of  f3-lactamases and ESBLs 
 13-Lactamases are most commonlyclassified according to 2 general 
schemes: Ambler molecular classification, and Bush-Jacoby-Medieros functional 
classification system.6 The molecular and functional classification schemes are 
aligned in Table  1.2.2 ESBLs are mostly  13-lactamases of Bush-Jacoby-Medieros 
group 2be and 2de, and those of Ambler classes A and D. 
     ESBLs initially arose from as a result of point mutation in the TEM and 
SHV  13-lactamases, which did not possess extended-spectrum  13-lactam 
substrate activity.9 For a number of years, TEM- and  SHV-type ESBLs were 
predominant. Several types of ESBLs, other than TEM and  SHV, have been 
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Table 1.2. Alignment of molecular and functional 13-lactamase classification 
schemes 2
Active Molecular Functional Typical enzymes Enzyme characteristics
site class class Typical substrates  Inhibitorsa
Serine A 2a Staphylococcal Penicillins CA, TZB
penicillinases
2b  TEM-1,  SHV-1 Penicillins, narrow-spectrum CA, TZB
cephalosporins
2be  ESBLsb  (TEM,  SHV, Penicillins, cephalosporins, CA, TZB
CTX-M families) monobactams (aztreonam)
2br TEM-IRT enzymes, Penicillins, narrow-spectrum TZB active
 SHV-10 cephalosporins Resistant to CA
2c PSE-1 Penicillins, including CA
carbenicillin
2e Proteus and Cephalosporins CA
 Bactericides
cephalosporinases
2f SME and  KPC  families; Penicillins, cephalosporins,  CA,  TZB
IMI-1 carbapenems
Serine C 1 AmpC, Chromosomal Cephalosporins Aztreonam,
cephalosporinases cloxacillin
Serine 2d  OXA-1,  OXA-10 Penicillins, including  (CA)`
 cloxacillin/oxacillin
2de OXA-ESBLs Penicillins, including  (CA)c
 cloxacillin/oxacillin;
cephalosporins except
cephamycins
2df OXA-24, OXA-40 Penicillins, including CA
 cloxacillin/oxacillin;
 carbapenems
Zinc B 3  L1, CcrA, VIM-and IMP Penicillins, cephalosporins, EDTA
families carbapenems, but not
aztreonam
 aCA clavulanic acid; TZB tazobactam; EDTA ethylenediaminetetraacetic acid 
 bExtended-spectrum  P-lactamase 
 cDependent upon specific enzyme 
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described, including the CTX-M-, OXA-, PER-type and several others.6 Among 
these, the CTX-M-type  ESBLs are a rapidly growing group and by far the most 
successful in terms of spread and their  impact.19 The name CTX-M reflects the 
potent hydrolytic activity of these ESBLs against cefotaxime antibiotics.9 
     The presence of ESBLs in various members of the Enterobacteriaceae 
family is of great microbiological and clinical importance and the CTX-M type of 
ESBLs are becoming increasingly more prevalent in E.  coli and K. pneumoniae.3 
The Infectious Diseases Society of America identified ESBL-producing 
Enterobacteriaceae as one of the six top priority dangerous pathogens for which 
there are few or no drugs in late-stage development, further making the choice of 
an appropriate and safe treatment for these infections limited.11 
1.5. Scope of the study 
     In this doctoral study I intended to address two basic issues regarding 
the rapidly spreading ESBLs, in particular CTX-M-type ESBLs. Firstly, we 
expanded the ESBL study beyond the traditional focus of hospital  settings, and 
studied the prevalence of faecal carriage of ESBL-producing microorganisms 
among asymptomatic individuals in communities. 
     Secondly, we tried to identify risk factors associated with the rapid 
spread of the ESBL producers in communities and to test possible reservoir 
populations such as nursing homes that may be acting as a bridge for spreading 
the ESBL-producing microorganisms between the hospitals and communities. 
     Furthermore, since antibiotic resistance is an international public health 
problem, we carried out this study in two 2 distinct countries, Thailand and Japan. 
This provided us with a possibility to compare the prevalence of and risk factors 
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associated with faecal carriage of ESBL-producing  Enterobacteriaceae in 
developed and developing nations.
11
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 CHAPTER 2. ESBL-PRODUCING ENTEROBACTERIACEAE IN 
         THREE PROVINCES OF THAILAND 
2.1. Background 
 Mu  ltid  rug-resistant Enterobacteriaceae that produce extended 
spectrum  13-lactamases (ESBLs) have spread rapidly worldwide causing 
treatment failure and hindering infection control  efforts.''  2The wide spread of 
ESBL-producing bacteria not only affects the choice of antimicrobials but may 
also cause excessive morbidity and mortality, as well as increased healthcare 
costs.3 
      Among the ESBLs, the CTX-M-type enzymes are more prevalent, and 
Escherichia  coli strains that produce CTX-M-type 13-lactamases are frequently 
true community-acquired ESBL-producing pathogens.2 These E.  coli strains 
cause community-acquired urinary tract and bloodstream infections.4'  5 The 
prevalence of and risk factors associated with the carriage of ESBL-producing 
microorganisms have often been studied in patients with these infections. This 
prevalence varies among countries, and risk factor analyses have shown 
conflicting and varying  results.''  4'  6'  7 In contrast, only a few studies have been 
performed on the community carriage of ESBL-producing E.  coil. In recent 
years, researchers have reported a 2.3, 3.7, 7.0 and  13.1% prevalence of 
ESBL-producing Enterobacteriaceae in healthy subjects in Lebanon, Spain, 
China and Saudi Arabia,  respectively.8-11 However, in a previous study by us, 
we observed a surprisingly high prevalence of CTX-M-type ESBL-producing 
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Enterobacteriaceae (82 of 160 samples) in asymptomatic individuals in 
Kanchanaburi province, Thailand. 12 
2.2. Objectives 
     The aim of the present study was to analyse the factors that may have 
contributed to the extensive spread of ESBL-producing Enterobacteriaceae in 
asymptomatic individuals in Thailand. We extended our study beyond the 
hospital environment and performed an epidemiological analysis of the risk 
factors in order to predict the possible threat of the spread of ESBL-producing 
Enterobacteriaceae. 
2.3. Materials and Methods 
Location of provinces 
     The study was conducted from May to July 2009 in Nan and Nakhon Si 
Thammarat provinces in Thailand. Epidemiological data from a previous study 
conducted in 2008 in Kanchanaburi province, Thailand, were also used in this 
study.12 
     The three provinces were selected to represent geographically different 
regions of the country: Nan is in the northern region, Nakhon Si Thammarat is 
in the southern region and Kanchanaburi is in the central region (Figure 2.1). 
Written informed consent was obtained from each individual participating in the 
study. 
Study samples 
     We analysed a total of 468 stool samples from the three Thai provinces: 
one sample was obtained from each asymptomatic volunteer. The participants 
were screened on the basis of age  (20 years) and medical history. 
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Asymptomatic individuals with a history of antibiotic treatment 3 months prior to 
sample collection and with a confirmed diagnosis of digestive tract diseases 
were excluded from the study.
Figure 2.1. Location of the Thai provinces selected for the study. 
Questionnaire 
     All participants were interviewed using a standardized questionnaire 
based on general demographic and socioeconomic ircumstances. They were 
questioned about their food intake, drinking water resources and toilet facilities. 
The participants were also questioned regarding their alcohol intake and 
smoking habits. We questioned them about their antibiotic usage, including the 
purchase of antibiotics without a prescription. After excluding the 
questionnaires in which age and gender data had not been filled in, we used 
445 questionnaires (183 men and 262 women) for statistical analyses. In 
Kanchanaburi, four of the excluded participants had ESBL-producing 
Enterobacteriaceae.
15
The following scheme shows the methodology used for the study.
Stool samples
MO
 www.rapidmicrobiology.com
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ESBL screening
DNA extraction
Bacterium stock ESBL confirmation 
fflo_111111011
Bacterial identification
PCR for  b/ao-rx_m and Drug susceptibility test 
group-specific genotyping
Scheme 2.1. The methodology of the research in schematic presentation. 
Screening tests for ESBLs 
     Stool samples were collected from asymptomatic participants to identify 
 ESBL-producing Enterobacteriaceae by phenotypic and genotypic methods. 
The phenotypic methods included plating the stool samples on MacConkey 
agar supplemented with 2  pg/ml cefotaxime  (`CTX-MacConkey) within 24 h 
after collection. A single colony was inoculated from CTX-MacConkey plates 
into a nutrient broth supplemented with 2  pg/mI cefotaxime and incubated at 
37°C for 24 h. The inoculated broth was used for preparation of bacterial stock 
and DNA extraction. 
                            16
     Subsequently, the ESBL production was confirmed by a double-disc 
synergy test as described  previously.12• 13 The test was performed on 
Mueller-Hinton agar with 30 pg disks of cefotaxime, ceftazidime, cefepime, and 
aztreonam and a disk of amoxicillin—clavulanate (containing 10 pg of 
clavulanate) positioned at a distance of 30 mm (centre to centre). The test is 
considered as positive when a decreased susceptibility to an antibiotic is 
combined with a clear-cut enhancement of the inhibition zone in front of the 
clavulanate-containing disk, often resulting in a characteristic shape-zone 
referred to as "champagne-cork" or "keyhole" (Figure 2.2).13
CMI, 14  (Suppl.1),  90-103
(a) The inhibition zone is enhanced between 
  cefotaxime (CTX) and amoxicillin—clavulanate 
  (AMC) disks, indicating synergy between 
   cefotaxime and clavulanate.
(b) The inhibition zones are enhanced between the 
  disks of cefotaxime, ceftazidime, cefepime,and 
  aztreonam and a disk of amoxicillin—clavulanate 
  positioned at the center.
Figure 2.2. Double disk synergy test. 
Identification of bacteria 
     Isolates were identified using conventional biochemical tests. Growth 
from a single colony was inoculated into biochemical test tubes with the following 
medium: TSI-Triple Sugar Iron; LIM-Lysine Indole Motility; SIM-Sulfide Indole 
Motility; MR-VP-Methyl Red-Voges Proskauer; SC-Simmons Citrate. The tests 
were read at 24 and 48 h. The isolates with unclear biochemical test results were 
identified by the API 20E system, according to the manufacturer's instructions 
(Sysmex-bioMerieux, Tokyo, Japan). 
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DNA extraction and PCR analysis 
     Bacterial DNA was extracted from the isolates by boiling the bacterial 
suspensions. DNA samples with a concentration of 0.1 ng/pl were used as 
template for PCR analysis. The universal primers CTX-M-U1 and CTX-M-U2 
were used to detect he  biac-rx_m gene, as described previously.14 DNA from the 
reference E. coil  biacncm-positive strain was used as a positive control. For 
genotyping the  b/ac-rx_m genes, we used four primer sets that amplify 
group-specific  biac-rx-m genes, as described elsewhere15: CTX-M-1 group, 
CTX-M-1, CTX-M-3,  CTX-M-10—CTX-M-12,  CTX-M-15, CTX-M-22, CTX-M-23, 
CTX-M-28, CTX-M-29 and CTX-M-30; CTX-M-2 group, CTX-M-2, 
CTX-M-4—CTX-M-7, CTX-M-20 and Toho-1; CTX-M-8 group, CTX-M-8; and 
CTX-M-9 group, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16—CTX-M-19, 
CTX-M-21, CTX-M-27 and Toho-2 (Table 2.1). 
Table 2.1. Primers used for PCR  amplification14,15
Target(s) Primer Sequence (5'  -  3' direction)
Product 
size (bp)
Annealing 
temp (°C)
CTX-M  CTX-M-U1
              CTX-M-U2 
CTX-M-1 group  CTXM  1-F3 
 CTXM  1-R2 
CTX-M-2 group  TOH01-2F 
 TOH01-1R 
CTX-M-8 group CTXM825F 
           CTXM825R 
CTX-M-9 group  CTXM914F 
 CTXM914R
 ATG  TGC  AGY  ACC  AGT  AAR  GTK                        593
ATG GC 
TGG GTR AAR TAR GTS ACC AGA 
AYC AGC GG 
GAC GAT GTC ACT GGC TGA GC 499 
AGC CG C  CGA  CGC  TAA  TAC  A 
 GCG  ACC  TGG  TTA  ACT  ACAATC C 351 
CGG TAG  TAT  TGC  CCT  TAA  GCC 
CGC TTT  GCC ATG  TGC  AGC  ACC 307 
GCT CAG TAC GAT CGA GCC 
 GCT  GGA  GAA  AAG CAG  CGG  AG 474 
GTAAGC TGA CGC AAC GTC TG
54a 
58a 
55
55
55
62
aMelting temperature .
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PCR reaction composition was setup as shown in Table 2.2: 
Table 2.2. PCR reaction composition 
Component Volume 
Water 1.2  pl 
2 x PCR buffer for KOD FX 5.0  pl 
2.0 pM deoxynucleotide triphosphates (dNTP) 2.0  pl 
10 pM CTX-M primer mix (5' and 3') 0.6  pl 
1.0  U/pl KOD FX (DNA Polymerase) 0.2  pl 
Template DNA  1.0  pl 
Total volume 10.0  pl 
     PCR amplification conditions were as follows: initial denaturation step 
at 94°C for 2  min; 35 cycles of denaturation at 98°C for 10 sec, annealing at 
55-62°C for 30 sec and extension at 68°C for 40 sec. The PCR products were 
visualized by 2% agarose gel electrophoresis followed by staining with  GelRed 
Nucleic Acid Gel Stain (Biotium). 
Antimicrobial susceptibility testing 
     All ESBL-producing Enterobacteriaceae isolates were tested for 
susceptibility to imipenem, meropenem, amikacin, gentamicin,  norfloxacin, 
ciprofloxacin and tetracycline by the disc diffusion method using an SN Disc 
(Nissui Pharmaceutical Co., Ltd, Tokyo, Japan) according to the manufacturer's 
instructions. Colonies from overnight growth on a nutrient agar plate were 
directly suspended in a sterile saline and vortexed thoroughly. Turbidity of the 
bacterial suspension was compared to the 0.5 McFarland standard 
(approximately 108 CFU/ml). Then a portion of the suspension was diluted 
1:100 with saline (106 CFU/ml). After adjusting the turbidity of the suspension, 
the Mueller-Hinton agar was inoculated with 100  pl of bacterial suspension 
which was spread using T-shaped spreader. Antimicrobial discs were applied to 
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the plates using sterile forceps. After overnight incubation at 37°C, the diameter 
of the zones of complete inhibition were measured. Zone diameter breakpoints 
are shown in Table 2.3. 
Table 2.3. Zone diameter breakpoints, mm 
Antimicrobial agent Susceptible Intermediate Resistant 
 Imipenem  ?. 16 14-15  5 13 
Meropenem 16 14-15  5 13 
Amikacin 17 15-16  5 14 
Gentamicin  ?. 15 13-14  5 12 
 Norfloxacin 17 13-16  5 12 
Ciprofloxacin 21 16-20  5 15 
Tetracycline 15 12-14  5  11 
Statistical analysis 
     Statistical analysis was performed using SPSS v.16.0. Data from the 
three provinces were examined separately for each province and for all 
provinces together. All variables were analysed by univariate analysis using a 
x2 test or Fisher's exact test, as appropriate. Statistical significance was set at 
P< 0.05. 
2.4. Results 
     The characteristics of the 445 study participants from Nan, Nakhon Si 
Thammarat and Kanchanaburi provinces in Thailand are listed in Table 2.4. 
The median age of the study participants was 54 years (range 25-86 years). 
The study participants were from the rural areas of Thailand and were 
predominantly farmers (72%). Sixty-two percent of the participants had 
received primary school education, whilst 26% had not received any formal 
education. 
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Table 2.4. Characteristics of the study participants 
Missing data were excluded from the analysis.
Variable Provinces
Nan
 (n=147)
Nakhon Si 
Thammarat 
 (n=144)
Kanchanaburi
 (n=154)
Age (years): median (range) 
Gender: male sex 
Education: no formal education 
Occupation: farmer 
Lifestyle 
 Current alcohol  uses 
 Current smokingb 
 Meat  consumptionc 
Housing condition 
 Tap water at home 
 Flush toilet at home
48 
70 
55 
132
72 
19 
138
54 
19
(30-71) 
(48%) 
(38%) 
(92%)
(50%) 
(13%) 
(94%)
(37%) 
(13%)
59 
53 
10 
89
23 
33 
127
51 
47
(39-86) 
(37%) 
(7%) 
(64%)
(18%) 
(23%) 
(88%)
(36%) 
(33%)
55 
60 
48 
88
68 
66 
145
106 
31
(25-86) 
(39%) 
(32%) 
 (61%)
(45%) 
(43%) 
(94%)
(70%) 
(20%)
aSubjects who drink alcoholic beverages once or more times amonth. 
bCurrent smoking includes both daily and non-daily or occasional smoking. 
 bSubjects who consume meat once or more times aweek. 
     The double-disc synergy test revealed that 32.0% (47 of 147 samples), 
32.6% (47 of 144 samples) and 53.9% (83 of 154 samples) of the isolates in the 
Nan, Nakhon Si Thammarat and Kanchanaburi provinces, respectively, were 
ESBL-producing bacteria. The prevalence of CTX-M-type ESBL-producing 
Enterobacteriaceae, as confirmed by phenotypic and genotypic methods, was 
29.3% in the Nan province (43 of 147 samples), 29.9% in the Nakhon Si 
Thammarat province (43 of 144 samples) and 50.6% in the Kanchanaburi 
province (78 of 154 samples) (Figure 2.3). The prevalence in Kanchanaburi 
was significantly higher than that in the other two provinces (P < 0.001). 
Genotyping of  b/ac-rx_m gene-positive isolates revealed that 33 (7.4%), 1 (0.2%)
21
and 127 (28.5%) of the 445 samples belonged to CTX-M-1, CTX-M-8 and 
CTX-M-9 groups, respectively (Figure 2.3). Three of the isolates did not belong 
to any of the groups tested.
-c) 
 a>  V
) 
 a) 
 ci) 
 U 
 a) 1E 
 (,) 
 15 
i'D-c=
 60% 
50% 
40% 
30% 
20% 
 10% 
0%
*
(n=147) 
 Nan
 (n=144) 
Nakhon Si 
Thammarat
 (n=154) 
Kanchanaburi
^ Unknown 
 ^ CTX-M-9 group 
^ CTX-M-8 group 
^ CTX-M-1 group 
 *P< 0 .001
Figure 2.3. Prevalence of CTX-M-type ESBL-producing Enterobacteriaceae and 
 b/ac-rx-m gene groups. 
 *P < 0.001; prevalence was compared between the provinces u ing ax2 test. 
     On performing bacterial identification for CTX-M-type ESBL-producing 
Enterobacteriaceae, we found that E.  coli was the predominant CTX-M-type 
ESBL-producing member of the Enterobacteriaceae in these isolates (40 of 43 
isolates in Nan, 39 of 43 isolates in Nakhon Si Thammarat and 70 of 78 isolates 
in Kanchanaburi) (Figure 2.4). The other CTX-M-type ESBL-producing bacterial 
species isolated were Citrobacter, Klebsiella and Enterobacter.
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 0 
  20% 
  10% 
   0%
 ^ Other 
    Enterobacteriaceae 
 ^ Citrobacter spp.
 ^  E.coli
          (n=147) (n=144)  (n=154) 
            Nan Nakhon Si Kanchanaburi 
 Thammarat 
Figure 2.4. Bacterial identification of CTX-M-type  ESBL-producing 
Enterobacteriaceae. 
     Antibiotic susceptibility tests showed that there was no CTX-M-type 
ESBL-producing isolate that was resistant or intermediate to imipenem, 
meropenem and amikacin. Tetracycline resistance was identified in 88.4% (38 of 
43), 86.0% (37 of 43) and 91.0% (71 of 78) of the samples in Nan, Nakhon Si 
Thammarat and Kanchanaburi provinces, respectively. Furthermore, 69.8% (30 
of 43), 62.8% (27 of 43) and 67.9% (53 of 78) of the isolates from Nan, Nakhon 
Si Thammarat and Kanchanaburi provinces, respectively, were resistant to 
gentamicin. Resistance to both ciprofloxacin and norfloxacin was identified in 10 
samples (23.3%) in Nan province, 14 (32.6%) in Nakhon Si Thammarat and 5 
samples (6.4%) in Kanchanaburi province. 
     Of the CTX-M-type ESBL-producing bacteria, 67.7% (111 of 164) were
23
resistant o two or more drugs tested and only 4.3% (7 of 164) were susceptible 
to all the antibiotics tested (Figure 2.5).
Figure 2.5. Multidrug resistance pattern of CTX-M-type ESBL-producing 
Enterobacteriaceae. 
CPFX, Ciprofloxacin; NFLX, Norfloxacin; GM, Gentamicin;  TC, Tetracycline. 
     No statistically significant association was observed between the 
presence of ESBL-producing bacteria and gender, age, education and food 
habits of or antibiotic usage by the participants (data not shown). However, on 
comparing antibiotic usage in the three provinces, we observed a significant 
difference between the three provinces. In particular, the pattern of antibiotic 
purchase without a prescription was similar to the pattern of the prevalence of 
ESBL-producing Enterobacteriaceae inthese provinces (Table 2.5). 
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Table 2.5. Comparison of antibiotic usage in the 3 provinces during the 
year
last
Variable Provinces
 Nan 
(n=147)
Nakhon Si 
Thammarat 
 (n=144)
Kanchanaburia  P  valueb 
  (n=154)
Antibiotic usage 
yes 65 (44.2%) 
no 81  (55.1%) 
 unknown or missing 1 (0.7%) 
Used and purchased antibiotics 
 without a prescription 34  (23.1%) 
 with a prescription 30 (20.4%) 
 unknown or missing 1 (0.7%)
94 (65.3%) 
48 (33.3%) 
2 (1.4%) 
34 (23.6%) 
56 (38.9%) 
4 (2.8)
104 (67.5%) 
44 (28.6%) 
 6 (3.9%) 
62 (40.3%) 
40 (26.0%) 
 2 (1.3%)
 <  0.001
0.006
aData for Kanchanaburi province was obtained from the previous study conducted bySasaki T 
 et  a1.12 
bBy x2 test. Missing or unknown data were excluded from the x2 test. 
2.5. Discussions 
     In this study, the prevalence of CTX-M-type ESBL-producing 
Enterobacteriaceae in asymptomatic Thai individuals (29.3-50.6%) was 
alarmingly high compared with that observed in previous studies performed on 
healthy subjects; these studies reported a  2.4-13.1% prevalence of faecal 
carriage of ESBL-producing Enterobacteriaceae in different  countries.811 A 
recent publication by Lo et al. reported 50.3% faecal carriage of 
ESBL-producing bacteria in household adults of children admitted to a 
paediatric department with mild febrile illness.16 In contrast, our study was 
conducted in community settings among healthy subjects. 
     The faecal carriage of ESBL-producing Enterobacteriaceae in 
asymptomatic Thai individuals is close to or sometimes higher than the 
prevalence of ESBL-producing bacteria in clinical isolates collected from 
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patients in Thailand (30-48% in  2005-2007).17 18 Lactamases belonging to 
CTX-M-1 group (20 %) and CTX-M-9 group (77%) were predominant among 
the 164 CTX-M  6-lactamases identified in asymptomatic individuals; this 
pattern is identical to that of patient isolates in Thailand, where CTX-M-14 
(CTX-M-9 group) and CTX-M-15 (CTX-M-1 group) were the ESBLs mainly 
responsible for resistance in E.  coli.19'  20 Our findings suggest that 
ESBL-producing bacterial isolates obtained from clinical specimens in hospital 
settings represent only a fraction of the actual prevalence, and that a much 
more rapid and broader community-wide spread of ESBL-producing bacteria 
may already be under way. Therefore, an increase in the prevalence of 
ESBL-producing microorganisms among patients is to be expected in the 
future. 
     Even though the presence of ESBL-producing microorganisms was not 
associated with any of the risk factors examined in this study, the comparison of 
antibiotic usage between the provinces tudied suggested that unregulated and 
high consumption of antibiotics may be a risk factor for the high prevalence of 
 ESBL-producing Enterobacteriaceae. Previous studies have reported 
correlations between antimicrobial resistance and antibiotic  usage.10' 21 The 
reason that our analysis did not show a direct association between the 
presence of ESBL-producing bacteria and antibiotic usage could be that 
individuals who had recently undergone antibiotic therapy had been excluded. 
     Furthermore, several studies have linked the high prevalence of 
antibiotic-resistant bacteria in the human population to the use of antibiotics in 
the farming  industry.22-25 Recent studies have revealed an increased 
                           26
prevalence of ESBL-producing microorganisms in poultry at chicken  farms.26'  27 
Other studies have also reported that farmers may be more likely than the 
general population to acquire antibiotic-resistant bacteria of food-animal 
origin.28' 29 However, the current study did not reveal any direct association 
between the prevalence of ESBL-producing bacteria and meat consumption or 
the occupation of the participants. This may be because of the homogeneity in 
the population of farmers who participated in the study or because most of them 
only had backyard chickens and not big industrialized farms. Moreover, studies 
indicate that contamination of the environment by large amounts of 
antimicrobials and heavy metal pollution may also select for antibiotic 
resistance in nature and favour the dissemination of antibiotic resistance 
 genes.3° Therefore, in order to clarify these issues, environmental data 
collection should be considered for future studies. 
      In summary, faecal carriage of ESBL-producing Enterobacteriaceae 
among asymptomatic individuals in Thailand is very high, with some variations 
in the prevalence among the provinces. Epidemiological analysis suggested 
that the high prevalence of ESBL-producing Enterobacteriaceae may be linked 
to antibiotic abuse. 
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      CHAPTER 3. CTX-M-TYPE ESBL-PRODUCING 
  ENTEROBACTERIACEAE IN KANCHANABURI PROVINCE, 
 THAI  LAND 
3.1. Background 
     Recent s udies have noted high levels of extended-spectrum 
 8-lactamase (ESBL)-producing ram-negative bacilli in the Asia—Pacific region, 
particularly in India, China and  Thailand.1-3 In Thailand, high rates of the ESBL 
phenotype (26% of  Enterobacteriaceae clinical isolates) were reported as early 
as  1994-96,1 and the CTX-M-type ESBLs were first detected during  1998-99.4 
The emergence of  community-onset infection with  ESBL-producing Escherichia 
 coli in Thailand was reported after an analysis of specimens collected  in 
 2003-04.5 In 2004-05, the prevalence of ESBL-producing E.  coil and  Klebsiella 
pneumoniae causing healthcare-associated infections was 13.2% and 12.7%, 
respectively, and most strains harboured the  b/aux_m gene.6 ESBL producers 
continue to be widely disseminated in Thailand, and recent data from 2005-07 
showed that the prevalence of ESBL-producing isolates in different clinical 
specimens had increased to include  30.0%-40.1% of E.  coil and  27.1%-39.2% 
of K. pneumoniae  strains.' 
     The problem of ESBL production is no longer limited to community-onset 
or hospital-acquired infections. Faecal carriage of ESBL-producing 
Enterobacteriaceae, particularly the CTX-M producers, by asymptomatic 
individuals has been noted in many parts of the  world.5-12 The highest levels of 
ESBL were found in the people of Thailand and  China.13' 14 We previously 
reported significantly high levels of faecal carriage of CTX-M-type 
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 ESBL-producing Enterobacteriaceae in  asymptomatic volunteers in three 
provinces in the northern, southern and central regions of Thailand in  2008-09.13 
Among the three provinces, Kanchanaburi province had the highest number of 
 blac-rx-rvi carriers,15 and this high number may have been linked to antibiotic 
abuse.13 Based on our previous findings, we calculated an appropriate sample 
size for another prevalence study in Kanchanaburi province and developed a 
more comprehensive questionnaire to include different risk factors. 
3.2. Objectives 
     In order to identify factors contributing to the high prevalence of ESBL 
producers in asymptomatic people, we investigated a possible link between 
CTX-M ESBL-producing Enterobacteriaceae and previous antibiotic use or 
hospital admittance. 
3.3. Materials and Methods 
Sample size determination 
     The sample size was calculated using OpenEpi open source  softwarel6 
and Cochran's sample size calculation formula for categorical data.17 The 
population of Kanchanaburi province was 734394 people, according to the 
Population and Housing Census 2000  data.18 Our previous study indicated that 
the prevalence of CTX-M-type ESBL-producing Enterobacteriaceae was 50.6% 
in the Kanchanaburi province. The data were entered to following equation to 
calculate the study sample size: 
                          , P  (1—  P) 
               n = Z`  
                                     e2
• Z = level of confidence at 95% (standard value of 1.96) 
• P = estimated prevalence (50.6% in Kanchanaburi province) 
• e = margin of error at 5% (standard value of 0.05) 
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Using the above equation, the initial calculation of the sample size would be: 
                       n = 1.962 0.51 (1-0.51) =384                                  0
.052 
Finally, n is divided by 0.90 to adjust for an anticipated 10% non-response: 
 n  =  384  ÷  0.90  =  427 
Therefore, the final sample size required was 427. 
Specimen collection and questionnaires 
     The study was conducted in two randomly selected districts of 
Kanchanaburi province, Thailand: Thong Pha Phum district, which borders 
Burma; and Tha Maka district, located close to the capital city Bangkok (Figure 
3.1). The study volunteers were selected by random door-to-door sampling. A 
total of 450 people  aged  > 18 years were approached to participate in the study, 
of whom 33 people refused. 
     Single stoolsamples from 417 adult volunteers from both districts were 
collected in November 2010 and analysed. Participants were interviewed using a 
standardized questionnaire, and the following data were recorded for each 
participant: age; gender; education; employment; number of persons in the 
household; monthly household income; consumption of raw meat and 
vegetables; household water supply and toilet conditions; possession of 
animals; antibiotic usage in the previous year; antibiotic usage in the previous 3 
months; visits to a doctor or health officer during the previous year; admission to 
hospital in the previous year; and invasive procedures during the previous year. 
     This study was approved by the Ethics Committee of the Faculty of 
Tropical Medicine, Mahidol University, Thailand. Written informed consent was 
obtained from each individual participating in the study. 
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Figure  3.1. Location of the Kanchanaburi districts selected for the study. 
Screening for and confirming the presence of ESBLs 
     Stool samples were collected using Cary-Blair transport media. The 
samples were plated on MacConkey agar supplemented with 2  pg/mI cefotaxime 
 (`CTX-MacConkey') and incubated at 37°C for 24 h. ESBL expression was 
confirmed by the disc diffusion method on Mueller—Hinton agar using cefotaxime 
(30 mg) and ceftazidime (30 mg) with and without clavulanic acid (10 mg), as 
recommended by the Clinical and Laboratory Standards Institute  (CLSI).1 A .?. 
5-mm increase in a zone diameter for either antimicrobial agent tested in 
combination with clavulanic acid vs. its zone when tested alone was considered 
to be a positive test (Figure 3.2). Each set of samples was tested with CLSI 
quality control strains E.  coli ATCC 25922 and K. pneumoniae ATCC 700603.1
Figure 3.2. ESBL confirmation test. Positive test: increased zone 
diameter for cefotaxime and ceftazidime in combination with 
clavulanic acid (left hand side) vs. their zones when tested alone 
(right hand side).
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      Positive isolates were identified using conventional biochemical tests 
and the API 20E system (Sysmex-bioMerieux, Tokyo, Japan), as described in 
the previous chapter. 
Antimicrobial susceptibility testing 
     All ESBL-producing Enterobacteriaceae isolates were tested for 
susceptibility to imipenem, meropenem, amikacin, gentamicin, ciprofloxacin and 
tetracycline by the disc diffusion method using an SN Disc (Nissui 
Pharmaceutical Co., Ltd, Tokyo, Japan) according to the manufacturer's 
instructions. 
 biacrx-m gene identification and genotyping 
     The  b/ac-rmvi genes were identified and genotyped by PCR using DNA 
extracted by boiling suspensions of positive isolates. DNA samples at a 
concentration of 0.1 ng/pl were used as PCR templates and  b/ac-rx_m genes were 
amplified using the universal primers CTX-M-U1 and CTX-M-U2, as described 
 previously.2° DNA from a reference E.  coli  b/aux_m-positive strain was used as a 
positive control. For genotyping of the  btacTx_m genes, four primer sets were 
used to amplify group-specific  blac-D(..m genes, as described elsewhere.21 
     Phylogenetic grouping of the identified E.  co/i isolates was determined 
by triplex PCR, using a combination of two genes (chuA and yjaA) and the DNA 
fragment TSPE4.C2, as described elsewhere (Table 3.1 and Figure  3.3).22 PCR 
products were visualized by 2% agarose gel electrophoresis  and staining with 
 GelRed nucleic acid gel stain (Biotium, Hayward, CA, USA). 
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Table 3.1 . Primers used for PCR amplification22
Target(s) Primer Sequence (5' - 3' direction)
Product 
size (bp)
chuA
yjaA
TSPE4.C2
ChuA.1 
ChuA.2 
 YjaA.  1
YjaA.2 
 TspE4C2.1 
TspE4C2.2
 GAC GAA CCA ACG GTC AGG AT 
TGC CGC CAG  TAC CAA AGA  CA 
TGA AGT  GTC AGG AGA CGC TG 
ATG GAG AAT GCG TTC CTC AAC 
GAG  TAA  TGT CGG  GGC  ATT  CA 
CGC GCC AAC  MA GTA TTAC G
279
211
152
rchwi
 Appl Environ Microbiol 66: 4555-8 
Figure 3.3. Dichotomous decision tree to determine the phylogenetic group of 
an E.  colt strain by using the results of PCR amplification of the chuA and yjaA 
genes and DNA fragment TSPE4.C2. 
Statistical analysis 
     Datawere analysed using SPSS version 16 software. Categorical data 
were compared using the x2 test, and continuous data were compared using the 
Mann—Whitney U-test. Univariate and multivariate logistic regression analyses 
were used to determine risk factors associated with the faecal carriage of 
 ES8L-producing  Enterobacteriaceae. Factors identified as statistically significant
36
in the univariate analysis were included in a multivariate logistic regression 
model, and the results are presented as ORs with 95%  Cis. Statistical 
significance was set at P < 0.05. 
3.4. Results 
     In all, we analysed 417 stool samples, 232 of which were collected from 
Thong Pha Phum district and 185 of which were collected from Tha Maka district. 
Data on demographics, history of hospitalization, recent visits to doctors or 
health officers, and antibiotic use are shown in Table 3.2. There were no 
significant age or gender differences between participants from the two districts. 
However, participants from Tha Maka district had significantly better education 
and employment status, and more frequent use of antibiotics. 
Table 3.2. Characteristics of the study participants
Districts
Characteristic Thong Pha Phum 
    n=232
Tha Maka 
 n=185
P  values
Median age, years (range) 
Male gender 
No formal education 
Unemployed 
Visited a doctor or health officer within the 
last year 
Admitted to a hospital within the last year 
Was prescribed antibiotics within the last 
year 
Used antibiotics within the last year 
Used antibiotics within the last 3 months 
Used antibiotics without a prescription 
within the last year
48 (20-84) 
87 (37.5%) 
60 (26.0%) 
67 (29.0%) 
155 (68.0%) 
98 (42.4%) 
145 (63.9%) 
159 (68.8%) 
114 (50.0%) 
120  (53.1%)
46 (20-85) 
71 (38.4%) 
12 (6.5%) 
28 (15.1%) 
116 (64.4%) 
62 (34.8%) 
140 (76.5%) 
142 (78.0%) 
122 (68.2%) 
116 (64.1%)
 0.057 
 0.854 
 <  0.001 
 0.001 
 0.452 
 0.119 
 0.006 
 0.037 
 < 0.001 
 0.026
aCalculated by x2 or Mann Whitne
y U- tests, as appropriate.
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Genotypes of CTX-M ESBL producers 
     Phenotypic screeningand confirmation tests showed that 289 of 417 
(69.3%) samples contained ESBL-producing bacteria (Table 3.3). All the 289 
isolates were identified from different participants. After PCR analysis, 65.7% 
(274 of 417) of the isolates were found to be positive for the  b/ac-rx_m gene. The 
prevalence of CTX-M-type ESBL-producing Enterobacteriaceae was 
significantly higher in Tha Maka district than in Thong Pha Phum district 
(P<0.001). Genotyping of  biac-rx_m revealed that most CTX-M producers 
harboured genes belonging to the CTX-M-9 group (60.6%), followed by the 
CTX-M-1 group (38.7%). Only two (0.7%) of the  b/ac-rx_m gene-positive isolates 
belonged to the CTX-M-8 group, and no samples belonged to the CTX-M-2 
group. 
     Among the CTX-M ESBL-producing Enterobacteriaceae, 85.4% (234 of 
274) were identified as E.  coil and 4.7% (13 of 274) were identified as K. 
pneumoniae. The remainder of the CTX-M-type ESBL producers were 
Citrobacter, Enterobacter and other bacteria. Phylogenetic group analysis of the 
E. coil strains showed that the highest proportion (114 of 234, 48.7%) of isolates 
belonged to phylogenetic group A and the next highest proportion belonged to 
group  B1 (67 of 234, 28.6%) (Table 3.4). 
Antibiotic susceptibility 
     All CTX-M-type ESBL-producing isolates were susceptible or 
intermediate to imipenem, meropenem and amikacin, except for two isolates: 
one was resistant to imipenem, meropenem, tetracycline and gentamicin, and 
the other was resistant o amikacin and tetracycline. Moreover, 88.0% (241 of 
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Table 3.3. Detection of CTX-M-type  ESBL-producing Enterobacteriaceae
CTX-M  group
District Participants
 ESBL 
 phenotypes CTX-M  geneb  CTX-M-14  CTX-M-2e  CTX-M-81 CTX-M-99
Thong Pha Phum 
Tha Maka 
Total
232 
185 
417
148 63.8% 
141 76.2% 
289 69.3%
133 57.3% 
141 76.2% 
274 65.7%
48  36.1% 
58 41.1% 
106 38.7%
0 0.0% 
0 0.0% 
0 0.0%
2 1.5% 83 62.4% 
0 0.0% 83 58.9% 
2 0.7% 166 60.6%
aESBL phenotype was determined according to the Clinical and L
aboratory Standards Institute recommendations. 
 bCTX-M gene was determined by PCR . 
 cGenotype of CTX -M genes was determined by PCR . 
 dCTX-M-1 group includes CTX-M-1 and several other variants such as CTX-M-3 and CTX-M-15 . 
 eCTX-M-2 group includes CTX-M-2 and several other variants. 
 fCTX-M-8 group includes CTX-M-8 . 
 9CTX-M-9 group includes CTX-M-9 and several other variants such as CTX-M-14 .
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274) of them were resistant o tetracycline,  63.1% (173 of 274) to gentamicin 
and 19.7% (54 of 274) to ciprofloxacin (Table 3.5). Of CTX-M ESBL-producing 
bacteria, 56.4% (75 of 133) from Thong Pha Phum district and 70.2% (99 of 
141) from Tha Maka district were resistant to two or more of the antibiotics 
tested. The prevalence of such multidrug-resistant CTX-M ESBL producers was 
significantly higher in Tha Maka district than in Thong Pha Phum district 
 (P<0.018). 
Table 3.4. Phylogenetic groups of the CTX-M ESBL-producing Escherichia  coli 
isolates
Phylogenetic 
           Thong Pha Phum 
  group
Tha Maka
A 
 B1 
B2 
 D 
Total
66 54.5% 
34 28.1% 
 4 3.3% 
17 14.1% 
121 100.0%
48 42.5% 
33 29.2% 
12 10.6% 
20 17.7% 
113 100.0%
Table 3.5. Antibiotic susceptibility of CTX-M-type ESBL-producing 
Enterobacteriaceaea
Susceptible Intermediate Resistant
Antimicrobial agent
n (%) n (%) n (%)
 Imipenem 
Meropenem 
Gentamicin 
Amikacin 
Ciprofloxacin 
Tetracycline
273 (99.6) 
273 (99.6) 
94 (34.3) 
272 (99.3) 
208 (75.9) 
33 (12.0)
0 (0.0) 
0 (0.0) 
7 (2.6) 
1 (0.4) 
12 (4.4) 
0 (0.0)
 1 (0.4) 
 1 (0.4) 
173 (63.1) 
 1 (0.4) 
54 (19.7) 
241 (88.0)
aSusceptibility results were interpreted according to SN Disc  (Nissui Pharmaceutical, Co, Ltd., 
Tokyo, Japan) zone diameter breakpoints.
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Risk factors for faecal carriage 
     Using univariatelogistic regression models, we found that the following 
factors were associated with a risk of carrying CTX-M-type ESBL-producing 
Enterobacteriaceae: (i) enrolment in formal education (OR 2.095; 95%  CI 
1.251-3.508; P<0.004); (ii) a history of hospitalization within the last year (OR 
1.550; 95%  CI 1.009-2.381; P<0.045); (iii) use of antibiotics within the last year 
(OR 1.592; 95%  CI 1.018-2.491; P<0.041); (iv) use of antibiotics within the last 
3 months (OR 1.879; 95%  CI 1.241-2.844; P<0.003); and (v) being prescribed 
antibiotics within the last year (OR 1.569; 95% CI 1.015-2.424; P<0.042). 
However, the final multivariate logistic regression model identified enrolment in 
formal education (OR 2.245; 95%  CI 1.297— 3.884; P<0.004), a history of 
hospitalization within the last year (OR 1.643; 95%  CI 1.036-2.603; P<0.035) 
and use of antibiotics within the last 3 months (OR 1.883; 95%  CI 1.221-2.903; 
P<0.004) as the only variables independently associated with faecal carriage of 
CTX-M-type ESBL producers. The three variables significantly predicted 
carriage of CTX-M ESBL producers (x2=20.47; df=3; P<0.001). 
3.5. Discussions 
Genotypes of CTX-M ESBL producers 
     The results of this study confirmed our previous findings of a high 
prevalence  (29.3%-50.6% faecal  carriage13) of CTX-M-type ESBL-producing 
Enterobacteriaceae among asymptomatic individuals in rural Thailand. The 
current finding of 65.7% (274 of 417 samples) carriage of CTX-M ESBL 
producers in Kanchanaburi province shows a rapid spread of CTX-M-type 
ESBLs compared with our previous finding of 51.3% (82 of 160) prevalence in 
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2008.15 Moreover, we observed variations in the prevalence of ESBLs within 
the Kanchanaburi province: Tha Maka district, which had a better education 
and employment status and higher use of antibiotics (Table 3.2), also had a 
significantly higher prevalence of CTX-M ESBL producers than did Thong Pha 
Phum district (Table 3.3). To the best of our knowledge, these are the highest 
prevalences of ESBL-producing Enterobacteriaceae that have been reported 
among healthy subjects in the community to date. 
     Prevalent identification of ESBLs belonging to the CTX-M-9 (60.6%) 
and CTX-M-1 (38.7%) groups is consistent with previous findings of community 
and clinical isolates from  Thailand!'  13'  15'  23 A recent study in healthy people of 
China showed 50.5% faecal carriage of E.  coli producing ESBLs, mainly of the 
CTX-M-type, among which also the CTX-M-9 and CTX-M-1 groups were 
dominant (74.5% and  29.1%, respectively).14 Other Asian countries may soon 
follow the same pattern of rapidly spreading CTX-M ESBLs in the community. 
      In the current study, most ESBL producers were identified as E. coil 
belonging to phylogenetic groups A and B1. In China, phylogenetic groups D 
and A were found to be prevalent among ESBL-producing E.  coil strains in 
asymptomatic arriers.14 A report on the population genetics of E.  coli stated 
that commensal E.  coil strains isolated from Asia mainly belonged to 
phylogenetic groups A and  B1,24 whereas a recent worldwide dissemination of 
 bla genes encoding CTX-M-14 and CTX-M-15 was considered to be drivenby 
epidemic E.  coli strains belonging to phylogroup B2  (ST131).25-27 However, of 
the 234 CTX-M ESBL-producing E.  coli strains in this study, only 16 isolates 
belonged to phylogroup B2. After multilocus equence typing, 11 of these were 
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identified as strain  ST131, with 7 samples belonging to the CTX-M-9 group and 
4 to the CTX-M-1 group (data not shown). This indicates that horizontal plasmid 
transfer has played a more important role than clonal expansion in the current 
massive community spread of CTX-M-type ESBLs in Asia. 
Antibiotic susceptibility 
     Our findings are similar to those of hospital studies in Thailand, where 
all ESBL-producing E.  colt strains isolated from clinical specimens were 
susceptible to carbapenems, but 57.8% were resistant to gentamicin, 81.0% 
were resistant to ciprofloxacin and  89.1% were resistant to  tetracycline.' 
However,  quinolone resistance was lower (19.7%) in CTX-M ESBL producers 
isolated from asymptomatic people than in those isolated from clinical  samples. 
Risk factors for faecal carriage 
     Our risk factoranalyses show that even in the community  setting; 
previous healthcare contact and antibiotic exposure have a major contribution 
to the faecal carriage of resistant bacteria. A history of hospitalization within the 
last year and antibiotic use within the last 3 months indicated higher risks of 
carrying CTX-M ESBL-producing Enterobacteriaceae. However, these factors 
may be specific to countries where antibiotic management programmes are 
uncommon and antibiotics can be purchased over the counter without a 
prescription, which is the case in  Thailand.5'  7
     Previous antibiotic use and a history of hospitalization have been 
identified as risk factors for community-onset urinary tract infections  (UTIs) 
caused by ESBL-producing  bacteria,28-3° but have rarely been found to be risk 
factors for the faecal carriage of ESBL producers. Only one report, to our 
                           43
knowledge, has found a strong association between the use of antibiotics in the 
previous 3 months and the rectal carriage of ESBL-producing E.  coli in elderly 
people in community  settings.31 In contrast, most other studies showed that 
prior hospitalization or previous use of antimicrobial drugs was irrelevant for the 
faecal carriage of ESBL-producing Enterobacteriaceae in healthy  people.32'  33 
Neither have studies on faecal carriage of patients attending health centres or 
at admission to hospitals found association with prior antibiotic  use."'  34 Thus, 
although our results regarding risk factors for faecal carriage differ from 
previous findings, they are similar to factors associated with community-onset 
UTIs caused by ESBL producers. This similarity may be explained by the fact 
that faecal carriage of ESBL-producing E.  coli contributes substantially to the 
development of  UTIs and that almost half of these infections are caused by the 
same strains found in the faeces of patients before the development of  UTIs.36 
     Interestingly, we found a significant association between the faecal 
carriage of CTX-M producers and enrolment of the participants in formal 
education. Since the study was conducted in rural areas, enrolment in formal 
education may be a proxy for  socio-economic status. Therefore, it may indicate 
that those who have better socio-economic status can also afford and/or have 
better access to medical services, including over-the-counter antibiotics. 
      Furthermore, different factors, such as acquisition of ESBL-producing E. 
 colt from food or by person-to-person transmission from faecal carriers, 
dissemination of ESBL-producing E.  colt in the environment and carriage by 
domestic and wild animals, have been proposed to explain the extensive 
spread of ESBL-producing E.  colt in community settings.36 However, our 
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findings did not show any association between the faecal carriage of CTX-M 
producers and household conditions, food habits or animals possessed by the 
participants. 
     Finally, it is important to recognize that the current study was conducted 
only in one province of Thailand and the findings may not be representative of 
the whole country. In addition, the study was conducted in community settings 
among asymptomatic individuals and risk factor analysis for faecal carriage of 
ESBL producers was therefore based on the participants' self-reporting, which 
may have potential for recall bias with regard to factors such as previous 
antibiotic use. Despite these limitations, our data indicate that implementation 
of antimicrobial stewardship interventions, such as limitation of 
over-the-counter antibiotics, prescribing the proper antibiotics for the proper 
duration, and proper hospital infection control, can assist in the prevention of 
further spread of resistant bacteria among healthy people in rural  communities . 
     In summary, faecal carriage of CTX-M-type ESBL-producing 
Enterobacteriaceae among asymptomatic individuals in the Kanchanaburi 
province of Thailand remains alarmingly high. Public health efforts should focus 
on educating rural Thai communities and healthcare professionals on the 
proper use of antibiotics. 
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 CHAPTER 4. ESBL-PRODUCING  ENTEROBACTERIACEAE 
     AMONG ASYMPTOMATIC JAPANESE PEOPLE 
4.1 Background 
     Escherichia  coil strains that produce CTX-M-type  6-lactamases have 
become widely prevalent in the general population and are probably being 
imported into the hospital  community.' 
     In Japan, the prevalence of ESBL producers among clinical isolates has 
shown an increasing trend. In 2000, Komatsu et al.2 reported a 0.5% prevalence 
of ESBL producers in the feces of diarrhea patients. Another review reported 
prevalences of 0.6, 7.2, 10.0, and 14% in clinical isolates of E.  coli and  Klebsiella 
pneumoniae in Japan in 1990, 1995, 2000, and 2003, respectively.3 A hospital 
study in southwestern Japan showed that the prevalence of ESBL-producing 
bacteria increased from 3.6 to 15.2% between 2003 and  2009.4 However, little is 
known about the frequency of ESBL-producing bacteria in healthy Japanese 
people. 
4.2 Objectives 
     The aim of this study was to investigate the prevalence of the faecal 
carriage of ESBL-producing Enterobacteriaceae among asymptomatic 
Japanese adults. 
4.3 Materials and Methods 
     Stool samplesfrom adult volunteers in Osaka, Japan, were collected 
from July 2009 to June 2010. Written informed consent was obtained from each 
individual who volunteered to participate in the study. We analyzed a total of 218 
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samples, 1 from each participant. 
     All participantswere asked to fill out a standardized questionnaire 
including general demographic ircumstances, antibiotic usage within 3 months 
prior to sample collection, and lifetime history of hospitalization. 
     Stool samples were assessed for the presence of ESBL-producing 
Enterobacteriaceae by phenotypic and genotypic methods. The phenotypic 
methods included plating the stool samples on MacConkey agar supplemented 
with 2  fag/ml cefotaxime (CTX-MacConkey). The results were confirmed using 
cefotaxime and ceftazidime with and without clavulanic acid, as recommended 
by the Clinical and Laboratory Standards Institute.5 Isolates were identified using 
conventional biochemical tests. Tests for susceptibility to imipenem, meropenem, 
amikacin, gentamicin, ciprofloxacin, norfloxacin, and tetracycline were 
conducted by the disc diffusion method using an SN Disc (Nissui 
Pharmaceutical, Tokyo, Japan), as described in previous chapters. 
     Bacterial DNA was extracted from the isolates by boiling the bacterial 
suspensions. DNA samples with a concentration of 0.1 ng/pl were used as the 
templates for polymerase chain reaction (PCR) analysis. The universal primers 
 CTX-M-U1 and CTX-M-U2 were used to detect the  b/ac-rx-m gene, and the 
primers b/a-SHV.SE (5'-ATG CGT TAT  ATI CGC CTG TG-3') and  bla-SHV.AS 
(5'-TGC  TTT GTT  ATT CGG GCC AA-3') were used to detect the  b/asHv gene, 
as described previously.6 DNA from the reference E.  coil  b/ac-rx_m-positive strain 
was used as the positive control. The PCR products were visualized by 2% 
agarose gel electrophoresis, followed by staining with  GelRed Nucleic Acid Gel 
Stain (Biotium, Hayward, CA, USA). 
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     DNA sequencing was used for genotyping the  b/aux_m genes. First, the 
DNA fragment was extracted from agarose gel using QIAEX  II Agarose Gel 
Extraction Kit (QIAGEN, Valencia, CA, USA). Then cycle sequencing was 
performed using BigDye® Terminator v3.1 Cycle Sequencing Kit and purification 
was done using BigDye  XTerminator® Purification Kit, according to the 
manufacturer's instructions (Applied Biosystems, Foster, CA, USA). The 
nucleotide sequences were analyzed with CLUSTALW and BLAST software 
 (http://clustalw.ddbj.nig.ac.jp/top-j.  htm  I). 
     Statistical analysis was performed using SPSS v.16.0. Variables were 
analyzed by univariate analysis using x2 or Fisher's exact test, as appropriate. 
Statistical significance was set at P < 0.05. 
4.4 Results 
     The characteristics of the study participants are shown in Table 4.1. The 
participants were aged between 20 and 70 years, with a median age of 41.9 
years. Most had not used antibiotics within the 3 months prior to sample 
collection and most did not have a history of hospitalization. 
     Of the 218 samples, 65 (29.8%) showed bacterial growth on 
CTX-MacConkey agar and 14 (6.4%) showed ESBL production (Table 4.2). All 
the 14 isolates were identified from different participants. On PCR analysis, 
92.9% (13 of 14) of the ESBL-positive isolates were positive for the  b/aux-m 
gene, and  1 sample carried the  b/asHv gene. By genotyping of  b/ac-rx_m genes, 
CTX-M-14 (38.5%) and CTX-M-2 (30.8%) ESBL types were predominantly 
identified. The other samples harbored the CTX-M-8, CTX-M-3, and CTX-M-15 
types (15.4, 7.7, and 7.7%, respectively). 
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Table 4.1. Characteristics of the study participants
Variable Extended-spectrum 
 13-lactamase (ESBL)  (—)
ESBL (+) Total number
Antibiotic usage  within  3  months
 Lifetime  history  of  hospitalization
No. of participants 
Age group (years) 
 20-39 
 40-59 
 over 60 
Gender: 
 Male 
 Female 
ntibiotic age  i 
 Yes 
 No 
 Don't remember 
 ifetime  istory  f  t 
 Yes 
 No 
 Don't remember
62 
119 
23 
103 
101 
 : 
35 
160 
 9 
 atioi 
72 
130 
 2
(91.2%) 
(95.2%) 
(92.0%) 
(92.8%) 
(94.4%) 
(89.7%) 
(94.7%) 
(90.0%) 
(94.7%) 
(92.9%) 
(100.0%)
6 (8.8%) 
6 (4.8%) 
2 (8.0%) 
8 (7.2%) 
6 (5.6%) 
4 (10.3%) 
9 (5.3%) 
1 (10.0%) 
4 (5.3%) 
10 (7.1%) 
0 (0.0%)
218 
68 
125 
25 
111 
107 
39 
169 
10 
76 
140 
 2
     Among the CTX-M ESBL-producing  Enterobacteriaceae, 84.6% (11 of 
 13) were identified as E.  coli and 15.4% (2 of 13) as K. pneumoniae. The 
SHV-type ESBL producer was identified as E.  coll. We did not identify any 
participants who harbored both ESBL-producing K. pneumoniae and E.  coli as 
well as different CTX-M genotypes. Antibiotic susceptibility tests showed that 
92.9% (13 of 14) of the ESBL-positive bacteria were susceptible to all the tested 
antibiotics, except for tetracycline. Five of the 14 ESBL producers were resistant 
to only tetracycline, and 1 was resistant o gentamicin and quinolones in addition 
to tetracycline. 
     Statistical analysis did not reveal any significant association between 
ESBL production and antibiotic usage or hospitalization experience, although
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Table 4.2. Detection of CTX-M-type  ESBL-producing Enterobacteriaceae
Genotype of CTX-M  genes°
Participants ESBL                     CTX -M geneb Organisms 
tested  phenotype' CTX-M-1 
 groups
CTX-M-2 
 group'
CTX-M-8 
 groupf
CTX-M-9 
 group9
218 14 (6.4%) 13 (92.9%)
Escherichia  coli
 Klebsiella pneumoniae
Total
 11 
(84.6%) 
 2 
(15.4%) 
 13 
(100%)
 1 
 (CTX-M-15) 
 1 
(CTX-M-3) 
   2 
 (15.4%)
  4 
(CTX-M-2)
0
 4 
(30.8%)
  2 
(CTX-M-8)
0
 2 
(15.4%)
   4 
 (CTX-M-14) 
 1 
 (CTX-M-14) 
   5 
 (38.5%)
 'ESBL phenotype was determined according to the Clinical and Laboratory Standards Institute recommendations. 
 "The CTX-M gene was determined by polymerase chain reaction (PCR). 
 °The  genotype of CTX-M genes was determined by DNA sequencing. 
 dThe  CTX-M-1 group includes CTX-M-1 and several other variants, such as CTX-M-3 and CTX-M-15. 
 'The CTX-M-2 group includes CTX-M-2 and several other variants. 
 fThe CTX-M-8 group includes CTX-M-8. 
 gThe  CTX-M-9 group includes CTX-M-9 and several other variants, such as CTX-M-14.
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these findings may be attributed to the small number of ESBL-positive cases 
identified in this study. 
4.5 Discussions 
     To the best of our knowledge, this is the first published data regarding 
the prevalence of ESBL-producing Enterobacteriaceae among healthy Japanese 
adults. Other countries have reported a  2.4-13.1% prevalence of faecal carriage 
of ESBL-producing Enterobacteriaceae in healthy  people.7-1° This value reached 
58.2% in developing countries, such as Thailand, where antibiotics are used 
without prescription.11 However, in Japan, where antibiotic usage is strictly 
regulated, the 6.4% prevalence of ESBL-producing Enterobateriaceae among 
healthy individuals is relatively high. 
     The high prevalence(92.9%) of CTX-M-type ESBLs identified in the 
present study is consistent with the global trend of CTX-M dominance. The 
prevalence of the CTX-M-14 enzyme belonging to the CTX-M-9 group and the 
CTX-M-2 enzyme belonging to the CTX-M-2 group was compatible with the 
findings of previous studies carried out in hospital settings, which have reported 
that the CTX-M-9, CTX-M-2, and CTX-M-1 groups are the predominant 
CTX-M-type ESBLs in E.  coli in  Japan.3'  4'  12, 13 This similarity between the 
CTX-M-type ESBL groups identified in community and hospital settings may 
indicate that people who are already carriers of ESBL producers are visiting 
hospitals. In previous studies of clinical isolates in Japan, ESBL-producing 
bacteria showed co-resistance to fluoroquinolones.4' 14 However, our data 
showed that most of the ESBL producers (92.9%) identified from healthy 
individuals were susceptible to all antibiotics, except tetracycline. Furthermore, 
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our study did not show any significant association between the faecal carriage of 
 ESBL-positive Enterobacteriaceae and recent antibiotic use or hospitalization, 
which indicates the existence of other risk factors. Because the study enrolled 
only a limited number of participants, possible factors that contribute to the 
prevalence of ESBL-producing bacteria in healthy people in Japan should be 
investigated in a larger number of participants. 
     In summary, our results suggest that the prevalence of the faecal 
carriage of CTX-M-type ESBL producers, mostly E.  coli, by healthy Japanese 
people is rapidly increasing. This may be one of the causes of the dissemination 
of ESBL-producing bacteria in hospitals. A broader and more detailed study of 
the prevalence of ESBL producers in the community is needed to prevent 
potential treatment failures associated with serious infections caused by these 
bacteria. 
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  CHAPTER 5. ESBL-PRODUCING  ENTEROBACTER1ACEAE  AMONG 
           NURSING HOME RESIDENTS IN JAPAN 
5.1 Background 
     The detection rate of extended-spectrum 13-lactamases (ESBLs) in 
clinical isolates of Escherichia  coli and  Klebsiella pneumoniae in the Kinki 
region of midwestern Japan significantly increased from 0.2% to 7.3% and from 
0.0% to 2.4%, respectively, during a 10-year period from 2000 to 2009.1 Our 
recent study among healthy adults in the same region showed 6.4% prevalence 
of ESBL producers, most of which were CTX-M-type ESBLs.2 The reasons for 
the increased prevalence of ESBL producers in Japan have not been 
adequately investigated. In the USA and Europe, nursing homes have been 
identified as a reservoir of antibiotic-resistant bacteria and possibly play an 
important role in their emergence and  spread.3-5 
5.2 Objectives 
     Therefore, w  studied the prevalence of and risk factors associated 
with faecal carriage of CTX-M-type ESBL-producing Enterobacteriaceae 
among the residents of nursing homes. 
5.3 Materials and Methods 
     The study wasconducted from March to September 2010 in 3 nursing 
homes located in midwestern Japan. Nursing home A was a privately owned 
150-bed nursing home, whereas nursing homes B and C were 100- and 50-bed 
institutions, respectively, run by the local  government. 
    We analyzed 225 stool samples from the 3 nursing homes, and  1 sample 
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was obtained from each resident. Data on resident characteristics, including 
length of stay in the current nursing home, co-morbidities, and past and present 
antibiotic use, were collected from resident charts. Detailed information was 
also collected from resident charts in nursing home A, which had the highest 
prevalence of  ESBL-producing Enterobacteriaceae carriers. The information 
included residents' physical and mental health status, history of invasive 
procedures within the last 2 years, past and present urinary tract infections, 
history of stroke, and other health conditions, such as diabetes. 
    ESBL production was identified by phenotypicand genotypic methods, 
as described elsewhere.2 The phenotypic methods included plating the stool 
samples on MacConkey agar supplemented with 2  pg/mI cefotaxime 
(CTX-MacConkey). ESBL expression was confirmed using cefotaxime and 
ceftazidime, with and without clavulanic acid, as recommended by the Clinical 
and Laboratory Standards Institute (CLSI), and each set of samples was tested 
with CLSI quality control strains E.  coli ATCC 25922 and K. pneumoniae ATCC 
700603.6 Isolates were identified using conventional biochemical tests. Drug 
susceptibility tests for imipenem, meropenem, amikacin, gentamicin, 
ciprofloxacin, norfloxacin, and tetracycline were performed with the disc 
diffusion method using SN Discs (Nissui Pharmaceutical Co. Ltd., Tokyo, 
Japan). 
     Bacterial DNA was extracted from the isolates by boiling the bacterial 
suspensions. DNA samples with a concentration of 0.1  ng/pl were used as a 
template for PCR analysis. The universal primers CTX-M-U1 and CTX-M-U2 
were used to detect the  blacncro gene, as described  previously.' DNA from the 
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reference E.  coli  b/aux_m-positive strain was used as a positive control. For 
genotyping the  b/ac-rx_m genes, we used 4 primer sets that amplify 
group-specific  b/ac-rx_m genes, as described  elsewhere.8 To identify the qnrA, 
 qnrB, and  aac(67-lb genes, PCR analysis was performed on the samples 
collected from nursing home A, as described  elsewhere.8'10 PCR products were 
visualized on 2% agarose gel electrophoresis followed by staining with  GelRed 
Nucleic Acid Gel Stain (Biotium, Hayward, CA, USA). 
     Statistical analysis was performed using SPSS v.16.0. All qualitative 
variables were analyzed using the x2 or Fisher's exact tests, and quantitative 
variables were analyzed with the Mann-Whitney U test, as appropriate. Factors 
identified in univariate models as being statistically significant were included in 
the multivariate logistic regression model and are presented as odds ratios with 
 95% confidence intervals. Statistical significance was set at P < 0.05. 
5.4 Results 
     The characteristics of the 225 study residents from the 3 nursing homes 
are listed in Table 5.1. The median age of the residents was 85 years (range, 
52-100 years). The majority (74.7%) of the residents were women. The median 
length of stay in the 3 nursing homes varied from 87 to 300 days. 
    Bacterial growth on CTX-MacConkey agar was observed in 103 of 225 
samples (45.8%). The prevalence of CTX-M-type ESBL-producing 
Enterobacteriaceae, as confirmed by phenotypic and genotypic methods, was 
22.9% (33 of 144 samples) in nursing home A, 18.8% (9 of 48 samples) in 
nursing home B, and 6.1% (2 of 33 samples) in nursing home C (Table 5.2). 
E.coli was the predominant CTX-M-type ESBL-producing bacterium among 
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these isolates (41 of 44 isolates). Genotyping of  biac-rx_m gene-positive isolates 
showed that 30 (68.2%), 13 (29.5%), and 1 (2.3 %) of the 44 samples belonged 
to groups CTX-M-9, CTX-M-1, and CTX-M-2, respectively. 
Table 5.1. Characteristics of the study participants
Nursing home
Variable A B C
Capacity 
No. of participants 
Age, years 
Gender 
Length of stay, 
days
Median (range) 
Female sex 
Median±SDa 
(range)
    150 
    144 
 85.0(53-100) 
    71.5% 
300±345  (2-1490)
  100 
   48 
86.5  (52-100) 
  83.3% 
 105±194 
 (2-1015)
  50 
  33 
84.0 (60-98) 
  75.8% 
 87±136 
 (8-630)
aSD
, standard deviation 
Table 5.2. Prevalence of ESBL-producing Enterobacteriaceae in nursing 
homes
Nursing home Total
A B C
No. of participants 
ESBL-producing Enterobacteriaceae 
CTX-M-type ESBL 
   Bacterial species 
            E.  coli 
            other Enterobacteriaceae
 144 
 37 
(25.7%) 
 33 
(89.2%) 
 31 
(93.9%) 
 2 
(6.0%)
 48 
  9 
(18.8%) 
  9 
(100.0%) 
  8 
(88.9%) 
  1 
(11.1%)
 33 
  3 
 (9.1%) 
  2 
(66.7%) 
  2 
(100.0%) 
  0 
(0.0%)
 225 
 49 
(21.7%) 
 44 
(89.8%) 
 41 
(93.2%) 
 3 
(6.8%)
    Disc diffusion test for multidrug resistance revealed high levels of 
co-resistance of CTX-M-type ESBL producers to quinolone antibiotics (33 of 33, 
8 of 9, and  1 of 2 isolates in nursing homes A, B, and C, respectively). More 
than half of these isolates (25 of 42) were resistant o tetracycline in addition to 
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quinolones. However, all the 44 identified CTX-M-type ESBL producers were 
susceptible to carbapenems and amikacin. Only  1 sample was susceptible to all 
the antibiotics tested, and another sample was resistant to gentamicin and 
tetracycline only. In nursing home A, where 100% (33 of 33 isolates) quinolone 
co-resistance was observed, we detected the  aac(6)-lb gene in 22 of the 33 
isolates (66.7%); however, none of the samples carried the qnrA or  qnrB genes. 
    Analysis of the data on resident characteristics howed no significant 
differences in terms of age, gender, or length of stay between carriers and 
non-carriers of CTX-M-type ESBL producers. Furthermore, carriers and 
non-carriers of CTX-M-producing bacteria did not differ in the current and past 
antibiotic use (data not shown). However, univariate analysis of the data 
collected from the resident charts in nursing home A revealed the following risk 
factors for CTX-M-type ESBL-producing Enterobacteriaceae carriage: (i) 
resident's condition that requires the highest level of care, (ii) inability to  turn-, 
over in bed, (iii) diaper use, (iv) diabetes, (v) urine infection, (vi) history of 
hospitalization within the last year, and (vii) invasive procedures within the last 2 
years (Table 5.3). In multivariate logistic regression analysis, inability to turn 
over in bed, diabetes, and invasive procedures within the last 2 years were the 
only variables independently associated with faecal carriage of CTX-M-type 
ESBL producers. 
5.5 Discussions 
    Our findings show that nursing homes in midwestern Japan have almost 
3 times higher prevalence (19.6%) of CTX-M-type ESBL producers than that 
reported in the previous clinical study and among healthy people in the same 
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 region.''  2 Thus, as predicted, nursing homes may play the important role of a 
reservoir in the rapid spread of CTX-M-type ESBLs in Japan. However, the 
prevalence of faecal carriage of ESBL producers in Japanese nursing homes is 
low compared to the findings in some other countries. 
Table 5.3. Univariate and multivariate logistic regression analyses of risk 
factors associated with CTX-M-type ESBL-producing Enterobacteriaceae 
carriage in nursing home A
Characteristics
Univariate analysis Multivariate analysis
OR (95%  CI) P value OR (95%  CI) P value
Required care  levels 
   Level 5 3.2 (1.29-7.914) 
  Level 1-4 1 
Ability to turn over in bed 
    Incapable 3.50  (1.56-7.86) 
  Capable 1 
Use of diapers 
   Yes 2.61 (1.14-5.99) 
No  1 
Diabetes 
   Yes 2.78 (1.11-6.99) 
No  1 
Past and present urine infection 
   Yes 4.13 (1.61-10.56) 
No 1 
History of hospitalization within the last one year 
   Yes 3.16  (1.37-7.30) 
No  1 
Invasive procedures within the last two years 
   Yes 4.73 (2.06-10.85) 
No  1
0.009
0.002
0.021
0.025
0.002
0.006
<0.001
2.81 (1.18-6.70) 
 1
3.22 (1.11-9.32) 
 1
4.54  (1.87-11.01) 
 1
0.019
0.031
0.001
OR odds ratio, 95%  Cl 95% confidence interval 
 aRequired care level is assessed by the authorized professional people according to the Long 
Term Care system of Japan  11. Five levels of care are distinguished: Care Level 1 is defined as 
requiring partial care, whereas Care Level 5 is defined as impossible to live without care. 
                           64
In Northern Ireland, United Kingdom, 40.5% (119 of 294 samples) of nursing 
home residents were gut carriers of ESBL-producing E.  coli, which were also 
resistant to fluoroquinolones;3 in Bolzano, Italy, 41.4% of 111 residents in a 
long-term-care facility (LTCF) were colonized with ESBL-producing E.  coli.12 
    The dominance of CTX-M among the ESBLs in nursing homes is 
consistent with the global trend. The prevalent identification of E.  coli (93.2%; 
41 of 44 isolates) among the ESBL producers and the CTX-M-9 group 
dominance (68.2%; 30 of 44 isolates) are similar to the previous findings in 
Japan, both in clinical settings and among asymptomatic individuals.  2'  13' 14 
    Among the CTX-M-type ESBL-producing Enterobacteriaceae found in 
nursing homes, 95% (42 of 44 isolates) were co-resistant to quinolone 
antibiotics. A hospital study in Japan reported that most of the 
CTX-M-producing isolates were resistant to fluoroquinolones,14 whereas 
fluoroquinolone resistance was observed in only  7.1% (1 of 14 isolates) of 
asymptomatic ESBL carriers in Japan.2 However, all the CTX-M-producing 
Enterobacteriaceae isolated at the nursing homes were susceptible to 
carbapenems and amikacin. 
     Poor functional status, diabetes, and invasive procedures have also 
been previously identified as risk factors for ESBL colonization or infection 
among residents of LTCFs and general  patients.4'  5 Not only residents, but also 
11.6% of 69 staff members in an LTCF were colonized with ESBL-producing E. 
 co/i.12 These may imply contact transmission of CTX-M-type ESBL-producing 
Enterobacteriaceae. Furthermore, among the 3 studied nursing homes, faecal 
carriage of CTX-M-type ESBL producers was the lowest  (6.1%) in the nursing 
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home C. Infection control measures may be better implemented in the nursing 
home with fewer residents. Therefore, infection control must be closely 
monitored in nursing homes to prevent resident-to-resident, staff-to-resident, 
and vice versa transmission of ESBL producers. 
    In summary, nursing home residents in Japan have a high prevalence of 
CTX-M-type ESBL-producing  Enterobacteriaceae carriage, with a high level of 
co-resistance to quinolones. Further monitoring and public health efforts 
focusing on nursing homes are needed to control the spread of 
ESBL-producing bacteria in Japan's aging society.
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